Connect Biopharma Holdings Limited CNTB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -96.99% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -96.99% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -96.99% | -- |
| SG&A Expenses | -- | -- | -- | 16.44% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 0.22% | -- |
| Operating Income | -- | -- | -- | -89.86% | -- |
| Income Before Tax | -- | -- | -- | -118.82% | -- |
| Income Tax Expenses | -- | -- | -- | 90.34% | -- |
| Earnings from Continuing Operations | -- | -- | -- | -118.64% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -118.64% | -- |
| EBIT | -- | -- | -- | -89.86% | -- |
| EBITDA | -- | -- | -- | -92.12% | -- |
| EPS Basic | -- | -- | -- | -117.09% | -- |
| Normalized Basic EPS | -- | -- | -- | -153.42% | -- |
| EPS Diluted | -- | -- | -- | -116.14% | -- |
| Normalized Diluted EPS | -- | -- | -- | -151.46% | -- |
| Average Basic Shares Outstanding | -- | -- | -- | 0.57% | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | 0.33% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |